APLS FY 2021 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$67M-73.4% YoY

Gross Profit

$61M92.2% margin

Operating Income

-$536M-805.7% margin

Net Income

-$746M-1121.3% margin

EPS (Diluted)

$-8.84

Cash Flow

Operating Cash Flow

-$563M

Free Cash Flow

-$564M

Stock-Based Comp.

$71M

Balance Sheet

Total Assets

$882M

Total Liabilities

$683M

Stockholders' Equity

$199M

Cash & Equivalents

$640M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$67M	$251M	-73.4%
Gross Profit	$61M	$226M	-72.8%
Operating Income	-$536M	-$214M	-150.9%
Net Income	-$746M	-$345M	-116.4%